Pages that link to "Q35797043"
Jump to navigation
Jump to search
The following pages link to Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function (Q35797043):
Displaying 50 items.
- Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? (Q26744254) (← links)
- Type 1 diabetes (Q27000491) (← links)
- GLP-1 Agonists in Type 1 Diabetes Mellitus. (Q34677451) (← links)
- Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase A (Q35163101) (← links)
- Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1 (Q35180073) (← links)
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study (Q35331836) (← links)
- Nutrient induced type 2 and chemical induced type 1 experimental diabetes differently modulate gastric GLP-1 receptor expression (Q35372850) (← links)
- Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm (Q35682682) (← links)
- Liraglutide for treating type 1 diabetes (Q35939660) (← links)
- The role for gut permeability in the pathogenesis of type 1 diabetes--a solid or leaky concept? (Q36263439) (← links)
- Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes (Q36428062) (← links)
- Removal of duodenum elicits GLP-1 secretion (Q36868293) (← links)
- Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes (Q36972891) (← links)
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. (Q36994382) (← links)
- Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. (Q37110621) (← links)
- Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial (Q37633458) (← links)
- Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges (Q37670209) (← links)
- Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers (Q37670232) (← links)
- Regulation of glucagon secretion by incretins (Q37913515) (← links)
- The potential of incretin-based therapies in type 1 diabetes (Q37932721) (← links)
- The alpha-cell as target for type 2 diabetes therapy. (Q37977335) (← links)
- Potential role of non-insulin adjunct therapy in Type 1 diabetes. (Q38026900) (← links)
- Recent advances in incretin-based therapies (Q38026956) (← links)
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. (Q38055195) (← links)
- The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists (Q38088195) (← links)
- Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes (Q38129805) (← links)
- Role of pancreatic β-cell death and inflammation in diabetes (Q38134111) (← links)
- Complications of diabetes therapy. (Q38167147) (← links)
- Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors (Q38259869) (← links)
- Glucagon and type 2 diabetes: the return of the alpha cell. (Q38262673) (← links)
- Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. (Q38616170) (← links)
- Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes (Q38642435) (← links)
- Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus (Q38770952) (← links)
- Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development (Q38806457) (← links)
- Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus (Q38916838) (← links)
- Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. (Q39137501) (← links)
- Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis (Q39375164) (← links)
- Theranostic magnetic resonance imaging of type 1 diabetes and pancreatic islet transplantation (Q39500260) (← links)
- Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial (Q40223075) (← links)
- GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach (Q41465810) (← links)
- Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. (Q42008289) (← links)
- Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis (Q44236597) (← links)
- Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia (Q47607423) (← links)
- GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study (Q47743186) (← links)
- Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. (Q48340758) (← links)
- Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study (Q51055764) (← links)
- Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls (Q51319337) (← links)
- Hypolipidemic effect of Smallanthus sonchifolius (yacon) roots on diabetic rats: Biochemical approach (Q51368521) (← links)
- Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus. (Q52674501) (← links)
- Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes. (Q53836936) (← links)